300294 博雅生物
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入1,473,92418.38%1,734,9042,651,9802,758,7012,650,528
减:营业总成本1,228,09443.90%1,279,2682,087,5812,222,5202,170,313
    其中:营业成本675,00362.63%613,2151,252,8611,250,8711,140,200
               财务费用(12,433)-47.08%(25,574)(30,493)(25,278)(20,605)
               资产减值损失(660)-205.07%(83,825)(329,660)(52,610)(80,713)
公允价值变动收益48,373-20.46%65,58385,7355,10310,714
投资收益24,864218.28%13,06214,01438,73432,399
    其中:对联营企业和合营企业的投资收益------------
营业利润342,345-28.72%477,255355,225532,181443,057
利润总额341,335-28.95%477,714353,712532,002443,118
减:所得税费用(1,708)-102.51%81,185105,56386,51484,839
净利润343,043-16.82%396,528248,148445,488358,279
减:非控股权益81-129.92%(463)10,68313,29013,750
股东净利润342,962-16.90%396,992237,466432,198344,529

市场价值指针
每股收益 (元) *0.680-17.07%0.7900.4700.8600.790
每股派息 (元) *0.150-6.25%0.3200.3000.2000.150
每股净资产 (元) *15.2121.18%14.84814.51614.25013.348
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容